Rosetta Biosoftware has dipped a toe in the microarray-based diagnostics market in an agreement with Agendia that it announced last week.

Agendia, based in Amsterdam, is the developer of MammaPrint, a gene expression-profiling service that assesses the risk of breast cancer recurrence. Initially, Agendia plans to use Rosetta Resolver in its R&D pipeline to discover new gene expression signatures for future diagnostics, but the diagnostics company is hoping to eventually move the software downstream into clinical use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.